|27.32||-0.0300||-0.11%||Vol 2.51M||1Y Perf 38.03%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||35.57||Analyst Rating||Hold 2.60|
|Potential %||30.20||Finscreener Ranking||★★★ 49.21|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 51.52|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 52.57|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★ 47.09|
|Price Range Ratio 52W %||40.31||Earnings Rating||Strong Buy|
|Market Cap||4.51B||Earnings Date||2nd Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2021|
|Estimated EPS Next Report||0.97|
|EPS Growth Next 5 Years %||30.00|
|Avg. Weekly Volume||2.97M|
|Avg. Monthly Volume||1.63M|
|Avg. Quarterly Volume||1.20M|
Chemours Company (The) (NYSE: CC) stock closed at 27.32 per share at the end of the most recent trading day (a -0.11% change compared to the prior day closing price) with a volume of 2.51M shares and market capitalization of 4.51B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Chemicals industry, Basic Materials sector and employs 6500 people. Chemours Company (The) CEO is Mark P. Vergnano.
The one-year performance of Chemours Company (The) stock is 38.03%, while year-to-date (YTD) performance is 10.21%. CC stock has a five-year performance of 80.57%. Its 52-week range is between 19.52 and 38.87, which gives CC stock a 52-week price range ratio of 40.31%
Chemours Company (The) currently has a PE ratio of 19.40, a price-to-book (PB) ratio of 5.47, a price-to-sale (PS) ratio of 0.82, a price to cashflow ratio of 5.30, a PEG ratio of 2.32, a ROA of 3.44%, a ROC of 7.21% and a ROE of 32.17%. The company’s profit margin is 4.55%, its EBITDA margin is 13.20%, and its revenue ttm is $5.66 Billion , which makes it $34.28 revenue per share.
Of the last four earnings reports from Chemours Company (The), there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.97 for the next earnings report. Chemours Company (The)’s next earnings report date is 02nd Nov 2021.
The consensus rating of Wall Street analysts for Chemours Company (The) is Hold (2.6), with a target price of $35.57, which is +30.20% compared to the current price. The earnings rating for Chemours Company (The) stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Chemours Company (The) has a dividend yield of 3.57% with a dividend per share of $1.00 and a payout ratio of 78.00%.
Chemours Company (The) has a Sell technical analysis rating based on Technical Indicators (ADX : 11.48, ATR14 : 1.15, CCI20 : -133.45, Chaikin Money Flow : -0.40, MACD : -1.56, Money Flow Index : 41.18, ROC : -12.32, RSI : 27.91, STOCH (14,3) : 12.05, STOCH RSI : 0.20, UO : 25.99, Williams %R : -87.95), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Chemours Company (The) in the last 12-months were: Alisha Bellezza (Option Excercise at a value of $128 615), Alisha Bellezza (Sold 8 913 shares of value $322 383 ), Alvenia Scarborough (Option Excercise at a value of $43 290), Alvenia Scarborough (Sold 3 000 shares of value $102 390 ), David C. Shelton (Option Excercise at a value of $179 961), David C. Shelton (Sold 9 754 shares of value $341 390 ), Denise Dignam (Option Excercise at a value of $80 390), Denise Dignam (Sold 5 571 shares of value $188 634 ), E. Bryan Snell (Option Excercise at a value of $878 004), E. Bryan Snell (Sold 56 682 shares of value $1 263 442 ), Edwin C. Sparks (Option Excercise at a value of $823 116), Edwin C. Sparks (Sold 57 042 shares of value $2 059 216 ), Mark E. Newman (Option Excercise at a value of $616 654), Mark E. Newman (Sold 33 423 shares of value $1 169 805 ), Mark P. Vergnano (Option Excercise at a value of $6 562 117), Mark P. Vergnano (Sold 404 937 shares of value $11 805 281 ), Matthew S. Abbott (Option Excercise at a value of $128 615), Matthew S. Abbott (Sold 8 913 shares of value $317 392 ), Sameer Ralhan (Option Excercise at a value of $313 189), Sameer Ralhan (Sold 16 975 shares of value $594 125 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.